Content about Multiple sclerosis

June 20, 2011

Mylan has scored a victory in its efforts to make a generic version of a Teva drug for multiple sclerosis.

PITTSBURGH — Mylan has scored a victory in its efforts to make a generic version of a Teva drug for multiple sclerosis.

The U.S. District Court for the Southern District of New York denied Teva’s motion for a summary judgment finding no inequitable conduct in relation to Copaxone (glatiramer acetate).

May 25, 2011

Biogen Idec is looking to address the advantages and challenges female clinicians experience in treating patients living with multiple sclerosis through a new educational initiative.

WESTON, Mass. — Biogen Idec is looking to address the advantages and challenges female clinicians experience in treating patients living with multiple sclerosis through a new educational initiative.

April 28, 2011

Don Francisco's Coffee announced an exclusive and limited-edition coffee created for the Nancy Davis Foundation for Multiple Sclerosis.

LOS ANGELES — Don Francisco's Coffee announced an exclusive and limited-edition coffee created for the Nancy Davis Foundation for Multiple Sclerosis.

The 10-oz. Don Francisco's Blend to Erase MS ground coffee bags were created for the "Orange You Happy to Erase MS" awareness campaign and feature the Orange You Happy to Erase MS logo. The bold roast features a hint of smoky, caramel and dark chocolate flavors and retails for $7.99.

April 20, 2011

Laura Geller, whose beauty products are sold at Ulta and Macy's Impulse locations, has partnered with Race to Erase MS and the Nancy Davis Foundation for Multiple Sclerosis to help raise awareness and funds for those afflicted with MS by creating a limited-edition Bring on the Bronze beauty kit.

NEW YORK — Laura Geller, whose beauty products are sold at Ulta and Macy's Impulse locations, has partnered with Race to Erase MS and the Nancy Davis Foundation for Multiple Sclerosis to help raise awareness and funds for those afflicted with MS by creating a limited-edition Bring on the Bronze beauty kit.

The Bring on the Bronze kit is part of the "Orange Campaign" that the Nancy Davis Foundation is spearheading to raise awareness and funds for those with MS.

April 12, 2011

An investigational drug made by Teva Pharmaceutical Industries and Active Biotech for multiple sclerosis reduced disease relapses and prevented the progression of disability, according to late-stage clinical trial results announced Monday.

JERUSALEM — An investigational drug made by Teva Pharmaceutical Industries and Active Biotech for multiple sclerosis reduced disease relapses and prevented the progression of disability, according to late-stage clinical trial results announced Monday.

March 3, 2011

The Food and Drug Administration declined to approve a Merck KGaA drug designed to treat relapsing-remitting multiple sclerosis.

DARMSTADT, Germany — The Food and Drug Administration declined to approve a Merck KGaA drug designed to treat relapsing-remitting multiple sclerosis.

January 11, 2011

Bayer HealthCare Pharmaceuticals sought to reassure healthcare professionals and their patients that a recall of alcohol prep pads distributed with its multiple sclerosis drug did not affect the drug itself.

WAYNE, N.J. — Bayer HealthCare Pharmaceuticals sought to reassure healthcare professionals and their patients that a recall of alcohol prep pads distributed with its multiple sclerosis drug did not affect the drug itself.

The drug maker’s MS treatment Betaseron (interferon beta-1b) is distributed with prep pads made by Triad Group, which recently staged a recall of prep products due to potential contamination with Bacillus cereus bacteria, which would lead to life-threatening infections.

September 30, 2010

Teva Pharmaceutical Industries and Active Biotech announced promising results from a mid-stage trial of laquinimod,...

September 21, 2010

The Food and Drug Administration has approved a drug for reducing relapses in patients with...

SILVER SPRING, Md. The Food and Drug Administration has approved a drug for reducing relapses in patients with multiple sclerosis.

 

The FDA announced Wednesday the approval of Swiss drug maker Novartis’ Gilenia (fingolimod) capsules, saying it was the first oral drug that can slow the progression of disability in patients with MS and offered an alternative to injected drugs.

 

 

Around 400,000 people in the United States and 2.1 million worldwide have MS, according to the National Multiple Sclerosis Society.

September 9, 2010

Efforts by two generic drug makers to market a generic version of a drug for...

NEW YORK Efforts by two generic drug makers to market a generic version of a drug for multiple sclerosis hit an obstacle this week in a U.S. District Court.

 

The U.S. District Court for the Southern District of New York denied a motion for summary judgment filed by Sandoz and Momenta Pharmaceuticals that patents covering Teva Pharmaceutical Industries’ drug Copaxone (glatiramer acetate) are invalid due to indefiniteness.

 

 

July 13, 2010

The market for multiple sclerosis drugs, long dominated by biologics and injectables, soon could see...

June 14, 2010

The Food and Drug Administration has agreed to speed up the review of a Genzyme...

June 13, 2010

An advisory committee of the Food and Drug Administration unanimously recommended approval for an investigational...

June 8, 2010

German drug maker Bayer HealthCare said a 16-year follow-up to a clinical trial of one...

June 2, 2010

German drug maker Bayer HealthCare Pharmaceuticals has created an iPhone application that it called the...

May 23, 2010

Swiss biotech company Biogen Idec and U.S. drug maker Abbott have begun enrolling patients in...

March 25, 2010

Swiss drug maker Biogen Idec and Irish drug maker Elan Corp. have started enrolling patients...

January 20, 2010

An investigational drug for treating multiple sclerosis reduced progression of disability by more than 30%,...

January 19, 2010

A group of companies and organizations plan to collaborate to develop new treatments for multiple...

August 20, 2009

Most consumers may not know a lot about biosimilar equivalence, immunogenicity or what “monoclonal antibody”...

NEW YORK Most consumers may not know a lot about biosimilar equivalence, immunogenicity or what “monoclonal antibody” means, but they know that battling a chronic disease can be a frightening and financially devastating prospect. Teva’s new TV campaign is a very sobering reminder of what many already know at a time when all of America is focused on fixing health care.